report fiscal adjust ep
consensu expect lower forecast
low end compani guidanc rang coopervis revenu
perform strong weak divis adjust gross margin
bp year-over-year neg impact fiscal
adjust ep rel coo expect item weigh
coopervis adjust gross margin quarter includ increment
cost ad short-term maintain high custom servic level
equip write-off associ older hydrogel contact len line
transit silicon hydrogel product happen faster
anticip currenc movement lower coopervis
adjust gross margin bp year-over-year reduc adjust ep
compani guidanc assum
coo fiscal revenu increas year-over-year million
consensu expect million similar
estim million quarter coopervis achiev organ growth
roughli estim slightli higher
compani guidanc rang notabl divis sale led
clariti myday daili silicon hydrogel lens year-over-
year high-teen organ growth asia pacif coopersurg pro
forma organ growth also similar expect robust growth
paragard off-set weak fertil product
expect revenu adjust ep million
versu prior consensu expect million
oper issu weigh coopervis adjust
gross margin expect carryov impact
compani expect currenc movement reduc adjust ep
addit coo guidanc assum organ growth
coopervis organ growth coopersurg adjust
tax rate
total debt total asset
reduc adjust ep estim
primarili reflect lower adjust gross margin assumpt coopervis
said view coopervis oper issu long-term
concern expect return typic adjust ep growth
compani also remain encourag coopervis decis
invest grow key larg retail buy group account segment
point strength think invest along misight
organ growth divis maintain buy rate
increas price target
import pleas read disclosur disclaim page report
report fiscal adjust ep consensu expect lower
forecast low end compani guidanc rang coopervis revenu
perform strong weak divis adjust gross margin bp year-over-year
neg impact fiscal adjust ep rel coo expect
cooper compani incfisc adjust ep analysisnorthcoast research thousand except percentag per share gross gross sg sg oper oper net interest incom interest incom incom incom incom tax adjust net adjust net net net wghd com share ep ep revenu growth adjust ep growth analysi revenu compani report northcoast research estim factset coo fiscal revenu increas year-over-year million consensu
expect million similar estim million quarter total compani organ
growth roughli slightli estim driven weak coopersurg fertil
product busi howev acquisit growth approxim better anticip driven
strength paragard provid off-set
divis standpoint coopervis achiev fiscal organ growth approxim
estim slightli higher compani guidanc rang quarter
coopervis result led broad strength across geographi includ pro forma organ growth
asia pacif emea america product standpoint clariti myday daili silicon
hydrogel lens experienc particularli robust sale year-over-year pro forma organ growth basi
combin sale silicon hydrogel lens biofin avaira also improv year-over-year
coo initi acceler sale key larg retail buy group account appear good start
compani suggest increas invest quarter sale support well promot
activ capit opportun notabl still earli key account initi
benefit initi contract win fulli seen compani result well like futur
contract help give investor comfort coopervis abil maintain above-market growth
despit upcom competit daili silicon hydrogel len launch alcon bausch lomb
coopersurg report fiscal pro forma organ growth similar forecast
quarter divis result led strong acquisit revenu paragard year-over-year
million aid channel inventori expans channel inventori increas aid result
core growth paragard still clearli outpac coo initi expect compani decid
increas promot advertis support paragard well number sale rep
fiscal better capit product opportun
paragard sale strong larg off-set weak coopersurg fertil product sale
hurt channel inventori contract recent lifeglob acquisit consolid distributor
divis dealt re-regist product produc costa rica manufactur
facil total report pro forma organ growth neg fertil remov fiscal
sale carrier screen non-invasive prenat test compani exit contrast sale core
offic surgic product remain strong roughli organ contribut slightli neg pro
forma organ growth core coopersurg product quarter
exclud carrier screen non-invasive prenat test prior year revenu estim
coopersurg fiscal organ growth closer neg includ mid-teen declin fertil
product neg forecast
coo fiscal adjust oper margin declin bp year-over-year well
estim adjust sg expens similar forecast compani adjust
gross margin bp year-over-year well expect regard adjust gross
margin coopersurg deliv except strong result bp year-over-year driven
paragard acquisit howev off-set weak coopervis adjust gross margin
bp year-over-year item weigh coopervis adjust gross margin quarter
includ increment cost ad short-term maintain high custom servic level
compani undergo distribut center upgrad activ higher inventori equip write-off associ
older hydrogel contact len line transit silicon hydrogel product happen faster
anticip currenc movement lower coopervis adjust gross margin bp
year-over-year reduc adjust ep compani guidanc assum
expect revenu adjust ep million versu prior
consensu expect million oper issu weigh coopervis
adjust gross margin expect carryov impact compani expect currenc
movement reduc adjust ep addit coo guidanc assum organ
growth coopervis organ growth coopersurg adjust tax rate
phase standpoint compani also indic expect adjust oper incom declin
slightli year-over-year fiscal increas slightli year-over-year fiscal given time issu relat
currenc headwind carryov impact fiscal oper issu
overal reduc adjust ep estim primarili reflect lower
adjust gross margin assumpt coopervis said view coopervis oper issu
long-term concern expect return typic adjust ep growth compani also
remain encourag coopervis decis invest grow key larg retail buy group account
segment point strength think invest along misight myopia control
opportun help provid path toward sustain above-market organ growth divis
maintain buy rate increas price target
cooper compani inc annual incom statement analysi adjust northcoast research thousand except percent per share gross gross sg sg oper oper net interest interest incom incom incom incom tax minor net incom extra net margin extra extra net net wghd com share ep ep revenu growth adjust ep growth began exclud amort intang adjust ep follow sauflon acquisitionsourc compani report northcoast research estim disclosur
